Wendell David Associates Cut By $678,240 Its Abbvie (ABBV) Holding; 2 Analysts Are Bullish Dream Office Real Estate Investment Trust (TSE:D.UN) Last Week

May 27, 2018 - By Dolores Ford

AbbVie Inc. (NYSE:ABBV) Logo

Among 4 analysts covering Dream Office Real Estate Investment Trust (TSE:D.UN), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Dream Office Real Estate Investment Trust had 25 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Desjardins Securities with “Buy” on Monday, August 15. TD Securities maintained the shares of D.UN in report on Monday, February 27 with “Hold” rating. The stock of Dream Office Real Estate Investment Trust (TSE:D.UN) earned “Sector Perform” rating by Scotia Capital on Wednesday, January 25. Scotia Capital maintained the shares of D.UN in report on Friday, February 24 with “Sector Perform” rating. TD Securities reinitiated the shares of D.UN in report on Friday, October 2 with “Buy” rating. The stock of Dream Office Real Estate Investment Trust (TSE:D.UN) earned “Buy” rating by TD Securities on Tuesday, June 27. RBC Capital Markets upgraded Dream Office Real Estate Investment Trust (TSE:D.UN) on Monday, February 22 to “Outperform” rating. Scotia Capital maintained the stock with “Sector Perform” rating in Friday, November 11 report. TD Securities downgraded the shares of D.UN in report on Monday, June 6 to “Buy” rating. On Tuesday, January 31 the stock rating was maintained by Scotia Capital with “Sector Perform”. See Dream Office Real Estate Investment Trust (TSE:D.UN) latest ratings:

Wendell David Associates Inc decreased Abbvie (ABBV) stake by 5.88% reported in 2017Q4 SEC filing. Wendell David Associates Inc sold 7,065 shares as Abbvie (ABBV)’s stock declined 6.31%. The Wendell David Associates Inc holds 113,028 shares with $10.93M value, down from 120,093 last quarter. Abbvie now has $160.40 billion valuation. The stock decreased 2.00% or $2.06 during the last trading session, reaching $101.08. About 25.30 million shares traded or 230.32% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 39.20% since May 27, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.05, from 0.85 in 2017Q3. It fall, as 42 investors sold ABBV shares while 695 reduced holdings. 139 funds opened positions while 448 raised stakes. 1.06 billion shares or 0.35% more from 1.06 billion shares in 2017Q3 were reported. Leisure Cap Mngmt owns 2,404 shares. Shelter Ins Retirement Plan reported 75,700 shares. 10 reported 25,120 shares stake. Ifrah Inc holds 1.23% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 35,006 shares. Provident Trust has invested 0.06% of its portfolio in AbbVie Inc. (NYSE:ABBV). Optimum Investment Advisors holds 1.33% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 43,266 shares. Oakwood Capital Mngmt Ltd Ca reported 60,291 shares or 1.29% of all its holdings. Checchi Capital Advisers Limited Liability Company holds 0.24% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 18,538 shares. Moreover, Tru Of Toledo Na Oh has 1.37% invested in AbbVie Inc. (NYSE:ABBV). North Star Asset holds 0.3% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 34,403 shares. Kessler Invest Gru Ltd Liability has invested 1.45% of its portfolio in AbbVie Inc. (NYSE:ABBV). Axa stated it has 2.05 million shares or 0.78% of all its holdings. Zevenbergen Invests Limited Liability reported 3,262 shares. Patten reported 2,806 shares. The New York-based Clearbridge Invests Limited Com has invested 0% in AbbVie Inc. (NYSE:ABBV).

Since December 14, 2017, it had 0 insider buys, and 11 sales for $47.70 million activity. $2.95 million worth of AbbVie Inc. (NYSE:ABBV) was sold by Schumacher Laura J. 8,280 AbbVie Inc. (NYSE:ABBV) shares with value of $976,084 were sold by GONZALEZ RICHARD A. $119,351 worth of AbbVie Inc. (NYSE:ABBV) was sold by Michael Robert A.. The insider CHASE WILLIAM J sold 70,928 shares worth $8.31M. RICHMOND TIMOTHY J. also sold $8.57 million worth of AbbVie Inc. (NYSE:ABBV) on Monday, December 18. 83,574 shares valued at $9.57 million were sold by ALBAN CARLOS on Wednesday, February 28. SALEKI-GERHARDT AZITA sold $157,458 worth of stock.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 earnings per share, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $3.13B for 12.83 P/E if the $1.97 EPS becomes a reality. After $1.87 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

Among 23 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 11 Hold. Therefore 43% are positive. Abbvie Inc had 92 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of AbbVie Inc. (NYSE:ABBV) earned “Underperform” rating by BMO Capital Markets on Wednesday, May 23. BMO Capital Markets maintained the stock with “Underperform” rating in Friday, March 23 report. The firm has “Buy” rating by Goldman Sachs given on Friday, March 10. Leerink Swann downgraded the stock to “Hold” rating in Monday, January 29 report. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Thursday, March 22 by SunTrust. The rating was initiated by Leerink Swann on Tuesday, October 18 with “Mkt Perform”. Bank of America maintained the stock with “Hold” rating in Monday, March 26 report. The company was upgraded on Monday, December 7 by Jefferies. The stock has “Sell” rating by Societe Generale on Wednesday, April 6. As per Thursday, March 22, the company rating was maintained by Leerink Swann.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 24, 2018, also Seekingalpha.com with their article: “AbbVie: Can Mylan Pull Off A Humira Biosimilar?” published on May 01, 2018, 247Wallst.com published: “Why One Old Stock Buyback Trick Is Working So Well for AbbVie” on May 01, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “Trump speech on drug prices light on specifics” published on May 11, 2018 as well as Fool.com‘s news article titled: “Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV)” with publication date: May 02, 2018.

AbbVie Inc. (NYSE:ABBV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>